United States Radioligand Therapy Market Expansion Supported by Precision Oncology & FDA Pipeline | Major Players: Eli Lilly and Company., Lantheus, Curium, AstraZeneca, ITM Isotope Technologies Munich SE, Telix Pharmaceuticals Limited, Oranomed, Sanofi

Radioligand Therapy Market reached US$ 2.41 billion in 2024 and is expected to reach US$ 15.80 billion by 2033, growing at a CAGR of 21.9% during the forecast period 2025-2033.

The Radioligand Therapy market analysis by DataM Intelligence delivers authoritative insights into the sector's growth, offering geographic coverage, demand outlook, and strategic trends that highlight both regional dominance and emerging opportunities. Beyond a surface-level overview, the research explores underlying drivers, breakthrough innovations, and market dynamics that could transform the Radioligand Therapy industry during the forecast period. Backed by in-depth data and expert evaluation, this study empowers stakeholders with reliable, actionable intelligence to navigate challenges, capture growth opportunities, and make informed decisions in a competitive global landscape. Will the Radioligand Therapy market emerge as the sector's next major growth frontier? The projections reveal the answer.

Request Sample Report to Access Investor Opportunity Matrix - Radioligand Therapy Market Deals & Growth Hotspots: https://www.datamintelligence.com/download-sample/radioligand-therapy-market?ophp

DataM Intelligence profiles some of the most reputed organizations present in the Radioligand Therapy market. They are as follows: Eli Lilly and Company., Lantheus, Curium, AstraZeneca, ITM Isotope Technologies Munich SE, Telix Pharmaceuticals Limited, Oranomed, Sanofi, RadioMedix, Inc., Clarity Pharmaceuticals, Ariceum Therapeutics, and Blue Earth Therapeutics, Novartis AG and Baye

Radioligand therapy delivers targeted radiation via radiopharmaceuticals that bind tumor antigens or receptors; the market is growing rapidly in oncology for prostate, neuroendocrine, and other receptor-positive cancers. Drivers include clinical efficacy, expanding indications, and development of new radioisotopes and delivery platforms. In the U.S., 2025 momentum includes broader adoption following regulatory approvals, build-out of nuclear medicine infrastructure, and supply-chain investments for isotope availability.

Radioligand Therapy Market Dynamics:

Growth Driver in Radioligand Therapy Market: Rising adoption of precision oncology and targeted cancer therapies drive radioligand therapy.

Restraints in Radioligand Therapy Market: High therapy costs and limited availability of isotopes restrain adoption.

Radioligand Therapy Market Opportunities: Expansion in prostate and neuroendocrine cancer treatments creates strong potential.

Radioligand Therapy Market Challenges: Regulatory hurdles and radiation safety concerns remain challenges.

Segment Covered in the Radioligand Therapy Market:

By Type (Lutetium Lu-177, Radium Ra 223 Dichloride, Others), By Target (Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR)), By Application (Prostate Cancer, Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs), Others

United States: Recent Industry Developments

✅ In September 2025, Novartis reported strong U.S. adoption of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for metastatic castration-resistant prostate cancer (mCRPC).
✅ In August 2025, the FDA granted Fast Track designation to RayzeBio's RYZ101, a radioligand therapy targeting gastroenteropancreatic neuroendocrine tumors.
✅ In July 2025, Actinium Pharmaceuticals advanced clinical trials for its Iomab-B radioligand therapy for leukemia patients.
✅ In June 2025, Lantheus Holdings expanded U.S. access to its PSMA-targeted diagnostics and therapies in partnership with academic hospitals.
✅ In May 2025, POINT Biopharma (Eli Lilly) launched new trial data on PNT2002, a radioligand candidate for prostate cancer treatment.

Europe: Recent Industry Developments

✅ In September 2025, the EMA approved Novartis' Pluvicto for earlier-line prostate cancer patients, broadening its market potential.
✅ In August 2025, Curium Pharma (France) launched Phase 3 trials of a new radioligand therapy for neuroendocrine tumors.
✅ In July 2025, Telix Pharmaceuticals expanded its Illuccix (Ga-68 PSMA-11) availability across Germany and the UK for imaging-guided therapy.
✅ In June 2025, ITM Isotope Technologies Munich SE secured funding to scale its theranostic radioligand production facilities.
✅ In May 2025, Advanced Accelerator Applications (Novartis) partnered with EU hospitals to expand access to radioligand therapies.

Asia: Recent Industry Developments

✅ In September 2025, China's regulatory body approved clinical trials for a domestic radioligand therapy candidate targeting prostate cancer.
✅ In August 2025, Telix Pharmaceuticals Japan expanded collaborations with hospitals for PSMA PET-guided radioligand treatments.
✅ In July 2025, India's Tata Memorial Centre initiated clinical trials for Lutetium-177-based therapies in prostate and neuroendocrine cancers.
✅ In June 2025, South Korea's Hanmi Pharmaceutical announced R&D investment into alpha-emitting radioligand therapies.
✅ In May 2025, FUJIFILM Toyama Chemical (Japan) advanced development of novel isotopes for radioligand therapy applications.

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=radioligand-therapy-market

Regional Analysis:

The global Radioligand Therapy Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa.

The report on Radioligand Therapy market delivers in-depth insights into new product launches, technological advancements, innovative services, and ongoing R&D activities shaping the industry. The study combines qualitative and quantitative analysis, incorporating tools such as PEST, SWOT, and Porter's Five Forces to evaluate the Radioligand Therapy market landscape, while also highlighting raw material sourcing, distribution channels, production capacities, supply chain structures, and detailed product specifications.

Regionally, North America leads the Radioligand Therapy market with strong R&D investments and early technology adoption, with the United States showing robust growth driven by high healthcare spending, innovation hubs, and favorable regulatory frameworks. Europe follows with a focus on sustainability and stringent standards, while Asia Pacific is the fastest-growing region supported by rapid industrialization, rising consumer demand, and government initiatives. South America exhibits steady expansion with improving economic conditions, and the Middle East & Africa show gradual progress fueled by infrastructure development, diversification, and increasing foreign investments.

Points Covered in this Report:

📌 Market Overview: This section outlines five key chapters, covering research scope, leading manufacturers, market segments, Radioligand Therapy market categories, study objectives, and the timeline considered for analysis.

📌 Market Landscape: Provides an evaluation of the competitive environment in the global Radioligand Therapy market, analyzing value, revenue, turnover, and market share by company, along with growth trends, recent transactions, sales performance, and competitive developments.

📌 Company Profiles: Examines the top players in the global Radioligand Therapy market, focusing on their sales performance, core products, pricing strategies, revenue, gross profit margins, and production growth.

📌 Regional Market Outlook: Offers a detailed breakdown of sales, revenue, supply, gross margin, CAGR, market share, and overall size across regions including North America, Europe, Asia Pacific, the Middle East & Africa, and South America.

📌 Market Segmentation: Presents in-depth research into how various applications, end-users, and product types contribute to overall market growth in the Radioligand Therapy market.

📌 Market Forecast - Production Side: Highlights projections for production volumes and values, forecasts for leading producers, and production trends by product type.

📌 Research Findings: Summarizes the key results and insights uncovered throughout the study.

📌 Conclusion: Concludes the report with final observations and insights drawn from the overall analysis.

Request Customized Market Entry Assessment for North America, EU, APAC: https://www.datamintelligence.com/customize/radioligand-therapy-market?ophp

People Also Ask:

Q.1. What are the key driving forces behind the growth of the Radioligand Therapy industry?
Q.2. Which factors are supporting market expansion, and which challenges are hindering the Radioligand Therapy market?
Q.3. What is the overall structure of the market, and what risks and opportunities does it present?
Q.4. How do pricing, revenue, and sales performance compare among the leading companies in the Radioligand Therapy market?
Q.5. What are the major market segments, and how is the Radioligand Therapy market categorized?
Q.6. Which companies hold a dominant position in the market, and what share do they command?
Q.7. What current and emerging trends are shaping the Radioligand Therapy market landscape?

Get Corporate Access to Live Radioligand Therapy Industry Intelligence Database: https://www.datamintelligence.com/reports-subscription

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.